We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Pet3.2

Petrelintide Research

Mostly mechanism / observational

5 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Petrelintide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from medium-quality randomised trials published 2021–2026 with a typical study size of 706 participants.

Based on 5 studies · 2 RCTs · 706 total participants

Confidence

Low confidence

By outcome

Weight loss & obesityIn a phase-1 multiple-ascending-dose trial, petrelintide reduced body weight by up to ~8.6% after 16 weeks in adults with overweight/obesity, with good tolerability · Over ~16 weeks
Mostly mechanism / observational4 studies
Glucose & metabolic
Mostly mechanism / observational4 studies
Safety profile
Too few graded studies2 studies

Active research area

5 studies in the last 5 years

20212026

1RCT2026

Brændholt Olsen M, Griffin J, Hövelmann U, Macura S, Fredsted Hagen B, Hesse D · Diabetes Obes Metab (2026)

View source

2RCTn=706 · large study2021

In plain English: Mean percentage weight reductions from baseline were greater with all doses of cagrilintide (0·3-4·5 mg, 6·0%-10·8%) versus placebo (3·0%)... Weight reductions were also greater with cagrilintide 4·5 mg versus liraglutide 3·0 mg (10·8% vs 9·0%).

Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH, Rubino D, Batterham RL. · Lancet (2021)

Amylin-class context, NOT petrelintide. This is the phase-2 trial of cagrilintide — the OTHER long-acting amylin analogue (sibling compound) — included as the best human-RCT evidence for what the amylin-analogue class can achieve
706 adults with overweight/obesity on once-weekly subcutaneous cagrilintide 0.3-4.5 mg vs liraglutide vs placebo over 26 weeks: ~6.0-10.8% mean weight loss vs 3.0% placebo, top dose modestly beating liraglutide 3 mg
GI events (nausea, constipation, diarrhoea) and injection-site reactions were the most frequent adverse events — the class-typical safety pattern petrelintide also shows

View source

3Review2026

In plain English: Several recently developed long-acting amylin analogues have shown strong efficacy as monotherapy in clinical trials: these include eloralintide, petrelintide, Met-233 and AZD6234.

Bailey CJ, Flatt PR, Conlon JM. · Peptides (2026)

Amylin-class context, NOT petrelintide-specific outcome data. Review of long-acting amylin-related peptides for obesity and type 2 diabetes, covering pramlintide, cagrilintide/CagriSema, amycretin, and petrelintide
Names petrelintide among recently developed long-acting amylin analogues 'shown strong efficacy as monotherapy in clinical trials' — but the detailed evidence summarised is for the broader class
Describes the established amylin mechanism: central satiety induction, slowed gastric emptying, suppressed prandial glucagon; GI side effects (especially nausea) common during initiation and up-titration but mostly resolving

View source

4Review2026

In plain English: The article is a review of the emerging preclinical and clinical data regarding the application of peptide-based amylin receptor agonists... including pramlintide and cagrilintide... and investigational drugs, including ZP8396 and amycretin.

Rejili M, Hussain MS, Khan Y, Haouala F, Ganesan S, Sahoo S, Pal A, Arora V. · Vascul Pharmacol (2026)

Amylin-class context, NOT petrelintide-specific outcome data. Review of amylin-receptor agonists for obesity, including pramlintide, cagrilintide, KBP-series DACRAs, and investigational agents including ZP8396 (petrelintide) and amycretin
Details amylin-receptor (calcitonin-receptor + RAMP) molecular biology and central homeostatic/hedonic feeding control — the mechanistic foundation for the class
Frames ZP8396/petrelintide as an investigational agent within an emerging class with enhanced pharmacokinetics and GLP-1 synergy potential

View source

5Preclinical2025

In plain English: Herein, we report the development of petrelintide, a potent, stable, long-acting analogue of human amylin that can be formulated at about neutral pH... Petrelintide is in clinical development as a potential treatment for weight management.

Fischer Munch H, Just R, Mosolff Mathiesen J, Eriksson PO, Skodborg Villadsen J, Vestergaard B, Deryabina M, Demmer O, Skarbaliene J, Hamprecht DW, Rist W, Baader-Pagler T, Grube A, Heim-Riether A, Giehm L. · J Med Chem (2025)

Petrelintide-specific. Medicinal-chemistry discovery/development paper (Zealand Pharma with Boehringer Ingelheim) describing the design of petrelintide to overcome amylin's amyloid aggregation and short half-life
Engineered for chemical stability while retaining in vitro and in vivo potency, and formulable at near-neutral pH to enable potential co-formulation with other weight-management peptides
Establishes petrelintide as a stable long-acting human amylin analogue selected for clinical development in obesity

View source

View in Research Library

Petrelintide Research

Mostly mechanism / observational

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials.

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.

Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.

Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.

Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue.